Oligonucleotide Therapeutics Market

Oligonucleotide Therapeutics Market: Global Industry Analysis and Forecast 2016 - 2024

Oligonucleotide Therapeutics Market Segmented By application such as Infectious diseases, Oncology, Neurodegenerative disorders, Cardiovascular diseases and Kidney diseases with type such as Antisense, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory and RNAi


Oligonucleotides are short chain RNA or DNA which are usually manufactured by utilizing automated synthesizers. Purification of the oligonucleotide is done by anion exchange chromatography which is followed by desalting and freezing technique. For the synthesis of siRNA duplex oligonucleotide, an annealing step is carried out where two purified oligonucleotide strands are brought together in an equimolar ratio.  

Oligonucleotide therapeutics are different from conventional medicine as they can inhibit the expression of certain genes. This has given rise to innovative new oligonucleotides that can target specific genes and treat chronic diseases. The development of oligonucleotide therapeutics is done through chemically modified artificial nucleic acids. The artificial oligonucleotides are being developed which has improved in vivo stability and enhanced affinity to target mRNA.

Find Out More about the Report Coverage

Oligonucleotide Therapeutics Market: Dynamics

The demand for oligonucleotides is expected to upsurge as there are very few approved molecules. This has offered oligonucleotide market players a wide scope to discover new molecular entities. Moreover, the technology upgrades of chemically synthesized oligonucleotides have led to the development of more stable and extended half-life molecules.

There are around 135 oligonucleotide therapeutics currently in different stages of drug development, which may further add to the limited three approved drugs currently available in the oligonucleotide therapeutics market.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Oligonucleotide Therapeutics Market: Segmentation

On the basis of application
  • Infectious diseases
  • Oncology
  • Neurodegenerative disorders
  • Cardiovascular diseases
  • Kidney diseases
  • Others 
On the basis of type
  • Antisense
  • Ribozymes
  • Aptamers
  • miRNA
  • CpG/Immunostimulatory
  • RNAi


Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

Oligonucleotide Therapeutics Market: Region-wise Outlook

The presence of the main market leaders, market consolidation and commercialization of new molecules are all contributing towards the dominating position of North America in the oligonucleotides therapeutic market. Miragen Therapeutics, Inc. agreed to merge with Signal Genetics, Inc for an initial investment of USD 40 million. Through this merger both the companies expect to develop micro RNA-targeted oligonucleotide clinical products.

New molecule application is also another strategy the market players are using to mark their presence in the oligonucleotide therapeutic market. Biogen recently received FDA approval for a new drug application for nusinersen. If approved, the antisense oligonucleotides molecule would be the first of its kind to be used for treating spinal muscular atrophy. 

Asia-Pacific is the fastest growing region as several oligonucleotide therapeutics manufacturers are looking forward to establishing manufacturing facilities in this region. Moreover, research undertaking and funding in the synthesis of oligonucleotides are expected to add on to the increasing demand.

Recently, Daiichi Sankyo Co., Ltd. announced its intention to open up a new company named Orphan Disease Treatment Institute Co., Ltd. to treat Duchenne muscular dystrophy through its active ingredient ENA oligonucleotide. The company is a collaboration between Daiichi, Mitsubishi UFJ Capital Co., Ltd. and Innovation Network Corporation of Japan and looks forward to entering the oligonucleotide therapeutics market.

Explore Persistence Market Research’s expertise in promulgation of the business !

Oligonucleotide Therapeutics Market: Market Players

One of the major trends driving the oligonucleotides therapeutic market is the increasing licensing and collaboration activities. Moreover, the demand for advanced technologies in oligonucleotide therapeutics such as gene silencing through RNAi is gaining importance due to its high efficiency, thereby propelling the oligonucleotide therapeutics market.   

Some of the key contributors to the oligonucleotide therapeutics market are PCI Biotech, SomaGenics, ContraVir, Alnylam, Regulus Therapeutics, Ionis Pharmaceuticals, Gilead, Santaris, InteRNA, miRage, Biogen, Merck and Pfizer, among others.


Fibromyalgia Treatment Market

Global fibromyalgia treatment market is projected to progress at a CAGR of around 7% from 2021 to 2031.

Combination Therapies In Aesthetics Market

Combination Therapies In Aesthetics Market - check share, size, revenue, valuation, CAGR, regional outlook, key players, competitive landscape, latest trends & forecast.

Traditional Chinese Medicine Market

Global Market Study on Traditional Chinese Medicine - explore how favourable regulatory & Reimbursement Scenario Supporting Market Expansion, CAGR, outlook, revenue & projections.

Alopecia Treatment Market

Global Market Study on Alopecia Treatment: High Demand for Effective Hair Loss Treatment. Explore it's market share, size, CAGR, revenue, trends, key players & forecast.

Our Clients

Our Clients